Pharmaceutical Development and Technology最新文献

筛选
英文 中文
Ezetimibe oral solid lipid nanoparticle by effervescent dispersion method: in vitro characterization and in vivo pharmacokinetic study in rats. 泡腾分散法制备依折替米口服固体脂质纳米粒体外表征及大鼠体内药代动力学研究。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-03-02 DOI: 10.1080/10837450.2025.2471461
Ruba S Darweesh, Farah S Al-Qawasmi, Mai S Khanfar
{"title":"Ezetimibe oral solid lipid nanoparticle by effervescent dispersion method: <i>in vitro</i> characterization and <i>in vivo</i> pharmacokinetic study in rats.","authors":"Ruba S Darweesh, Farah S Al-Qawasmi, Mai S Khanfar","doi":"10.1080/10837450.2025.2471461","DOIUrl":"10.1080/10837450.2025.2471461","url":null,"abstract":"<p><p>Ezetimibe (EZT) is a class II drug of the Biopharmaceutics classification system (BCS), with limited aqueous solubility and high permeability. This study aims to enhance the solubility and oral bioavailability of EZT by developing EZT solid lipid nanoparticles (SLNs). EZT-SLNs were developed through the effervescent dispersion technique. Different amounts of Tween-80, Compritol ATO 888, and mannitol as cryoprotectant were used. F11 was the optimum formula with 154 nm in size and 90.26% entrapment efficiency. It demonstrates significant enhancements in solubility across various pH values. In addition, F11 shows a significantly higher drug release than pure EZT at all time points, and that's related to the reduction in the particle size and increasing its surface area along with the transformation from a crystalline state to an amorphous state. The powder X-ray diffraction and Differential Scanning Calorimetry tests confirmed this conversion from crystalline form to amorphous. The <i>in vivo</i> animal study demonstrated that the C<sub>max</sub> and <math><mrow><msubsup><mrow><mtext>AUC</mtext></mrow><mrow><mn>0</mn></mrow><mrow><mtext>∞ </mtext></mrow></msubsup></mrow></math> of the EZT-SLNs group were significantly higher than the pure EZT group, after oral administration. In conclusion, EZT-SLNs with enhanced <i>in vitro</i> and <i>in vivo</i> properties were successfully developed using the effervescent dispersion technique.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"268-279"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering orally disintegrating tablets for buccal delivery of cilostazol with enhanced dissolution and bioavailability: a novel dual porogenic approach, in vitro characterization, and in vivo evaluation in rats. 具有增强溶解性和生物利用度的西洛他唑口腔崩解片:一种新的双重致孔方法,体外表征和大鼠体内评价。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-02-28 DOI: 10.1080/10837450.2025.2472887
Shahinaze A Fouad, Nada Abdelaziz, Mahmoud H Teaima, Mohamed El-Nabarawi, Amal Anwar Taha, Rehab Abdelmonem, Khaled El-Refai
{"title":"Engineering orally disintegrating tablets for buccal delivery of cilostazol with enhanced dissolution and bioavailability: a novel dual porogenic approach, <i>in vitro</i> characterization, and <i>in vivo</i> evaluation in rats.","authors":"Shahinaze A Fouad, Nada Abdelaziz, Mahmoud H Teaima, Mohamed El-Nabarawi, Amal Anwar Taha, Rehab Abdelmonem, Khaled El-Refai","doi":"10.1080/10837450.2025.2472887","DOIUrl":"10.1080/10837450.2025.2472887","url":null,"abstract":"<p><p>Cilostazol (CTZ), is a BCS class II drug with limited bioavailability. In the current study, orally disintegrating tablets (ODTs) for buccal delivery of CTZ were prepared by two methods; lyophilization (Lyo-ODTs) and direct compression (DC-ODTs). All CTZ-ODTs were evaluated for <i>in vitro</i> disintegration time (DT) and wetting time (WT) tests, <i>in vitro</i> dissolution. Scanning electron microscopic (SEM) analysis was performed for the selected Lyo-ODT-7 and DC-ODT-2. Lyo-ODT-7 composed of aerosil<sup>®</sup> 200 and PEG 4000 acquired the shortest DT (13.00 ± 0.14) and WT (33.00 ± 0.26) among the prepared ODTs. It also showed a 2.3 fold significantly enhanced dissolution profile at an early time point (5 min) that was maintained till 1 h, in simulated saliva fluid (pH ∼ 6.8), compared to Pletaal<sup>®</sup> IR tablets (<i>p</i> < 0.0001). SEM analysis revealed the remarkable porosity of Lyo-ODT-7, confirming its successfully enhanced disintegration and dissolution. Lyo-ODT-7 showed significantly enhanced pharmacokinetic parameters with a 3.5 and 3.6 fold increase in C<sub>max</sub> (<i>p</i> = 0.0493) and AUC<sub>0-24</sub> (<i>p</i> = 0.0470), respectively compared to Pletaal<sup>®</sup> IR tablets. The relative bioavailability of CTZ after buccal administration of Lyo-ODT-7 to rats was 364.45%, compared to the market oral IR tablets; Pletaal<sup>®</sup>. The enhanced bioavailability imposes the successful oromucosal absorption of CTZ <i>via</i> buccal delivery of Lyo-ODT-7. Our study demonstrated that Lyo-ODT-7 could represent a favorable buccal dosage form for patients with intermittent claudication, suffering from dysphagia. It can also be used in cases of acute cerebral or myocardial infarction due to its significantly enhanced rate and extent of absorption. It is considered a promising approach for buccal delivery of BCS class II active pharmaceutical ingredients (APIs) suffering from solubility problems and hepatic first pass effect.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"280-294"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143503322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of therapeutic effectiveness of developed colchicine transnovasomes in treatment of recurrent aphthous ulcer as monotherapy and combination therapy with platelet-rich plasma. 秋水仙碱转新酶体单药与富血小板血浆联合治疗复发性阿弗特溃疡的疗效评价。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-03-10 DOI: 10.1080/10837450.2025.2475967
Soha M Kandil, Iman I Soliman, Marwa Hosni, Abeer Salama, Ebtisam M Abdou
{"title":"Assessment of therapeutic effectiveness of developed colchicine transnovasomes in treatment of recurrent aphthous ulcer as monotherapy and combination therapy with platelet-rich plasma.","authors":"Soha M Kandil, Iman I Soliman, Marwa Hosni, Abeer Salama, Ebtisam M Abdou","doi":"10.1080/10837450.2025.2475967","DOIUrl":"10.1080/10837450.2025.2475967","url":null,"abstract":"<p><strong>Objectives: </strong>Transnovasomes is a new exciting class of lipid-based nanovesicles. Colchicine (COL) is a hydrophilic natural alkaloid with anti-inflammatory features having oral administration and permeation defects. Recurrent Aphthous Ulcer (RAU) is the most prevalent disease of the oral mucosa suffering from lack of a particular and final preventative therapy. So, designing a prolonged and effective specialized delivery system for ulcer treatment is important.</p><p><strong>Methods: </strong>Colchicine transnovasomes (COL-TNs) were prepared using surfactants (Span 60 & Span 80), free fatty acids (Oleic acid & Stearic acid), Cholesterol and Brij 58. COL-TNs were evaluated for their vesicle size (VS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE%), and <i>ex-vivo</i> permeation after 12 h (Q<sub>12h</sub>).</p><p><strong>Results: </strong>Values of VS, PDI, ZP, EE% and Q<sub>12h</sub> of the optimized formulation were 256.74 ± 11.2 nm, 0.322 ± 0.08, -43.3 ± 0.62, 85.35 ± 3.7% and 72.69 ± 5.84% respectively. Drug accumulation from the optimized formulation was ninefold greater than drug solution after 8 h. <i>In-vivo</i>, COL-TNs formulation, alone or in combination with platelet-rich plasma (PRP), achieved complete healing of acetic-acid induced RAU restoring normal levels of assayed biomarkers and normal oral mucosa histological features.</p><p><strong>Conclusions: </strong>COL-TNs can be used as a promising, safe, efficient treatment of RAU, as monotherapy or combination therapy with PRP.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"323-341"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation of diltiazem HCl-modified release formulation using cation-exchange resin as a single excipient. 以阳离子交换树脂为单赋形剂制备盐酸地尔硫卓改性缓释制剂。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-03-03 DOI: 10.1080/10837450.2025.2474092
Khouloud A Alkhamis, Suhair S Al-Nimry
{"title":"Preparation of diltiazem HCl-modified release formulation using cation-exchange resin as a single excipient.","authors":"Khouloud A Alkhamis, Suhair S Al-Nimry","doi":"10.1080/10837450.2025.2474092","DOIUrl":"10.1080/10837450.2025.2474092","url":null,"abstract":"<p><strong>Objective: </strong>Modified released formulations of diltiazem were previously prepared using cation-exchange resins. However, multiple excipients were required to achieve the appropriate release rate. It was of interest to prepare a modified release dosage form of diltiazem using drug-resin complex alone.</p><p><strong>Methods: </strong>Adsorption experiments conducted using a rotating bottle apparatus. The procedure involved adding the resin to the bottles, followed by appropriate amount of drug solution. The bottles were rotated until equilibrium was reached and the concentrations were analyzed using a reversed phase HPLC method, which effectively separated the compound from its degradation product. Release studies were conducted using a USP dissolution apparatus 2 with phosphate buffer as the dissolution medium.</p><p><strong>Key findings: </strong>Diltiazem was unstable inside the resin when the H<sup>+</sup> form was used. It became stable when the H<sup>+</sup> was displaced with Na<sup>+</sup>. Langmuir-like equation was applied to the adsorption isotherms. The equation parameters were influenced by the resin's cross-linking and particle size. Maximum drug release is related to sample volume. Positive linear relationship was obtained between initial release rate and extent of uptake.</p><p><strong>Conclusion: </strong>This study successfully demonstrates that Dowex® 50WX8 (Na<sup>+</sup> form) can be used as a single excipient in diltiazem formulations, providing both chemical stability and sustained release without requiring additional polymer coatings.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"306-313"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insight into manufacturing of bespoke combination drug products containing carvedilol and simvastatin by fused deposition modeling. 通过融合沉积模型洞察含有卡维地洛和辛伐他汀的定制联合药物产品的制造。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-03-14 DOI: 10.1080/10837450.2025.2475965
Lucas Korsgaard Andreasen, Emilie Victoria Slot Andreasen, Wuzhong He, Jukka Rantanen, Natalja Genina
{"title":"Insight into manufacturing of bespoke combination drug products containing carvedilol and simvastatin by fused deposition modeling.","authors":"Lucas Korsgaard Andreasen, Emilie Victoria Slot Andreasen, Wuzhong He, Jukka Rantanen, Natalja Genina","doi":"10.1080/10837450.2025.2475965","DOIUrl":"10.1080/10837450.2025.2475965","url":null,"abstract":"<p><p>The goal of this study was to explore the fabrication of a combination drug product containing two poorly soluble active pharmaceutical ingredients (APIs), carvedilol (CAR) and simvastatin (SIM), in therapeutically relevant doses (25 mg of each API) with a distinct, easily distinguishable shape. Fused deposition modeling, combined with hot-melt extrusion (HME), was used to produce hollow heart-shaped dual-loaded tablets in which the two APIs were spatially separated with an intermediate API-free layer. Water-soluble hydroxypropyl methylcellulose of varying molecular weights was used as the primary polymer for HME. The incorporation of a processability-improving polymer, such as polycaprolactone, was necessary to facilitate the printing of these delicate geometries and lower the printing temperature. The 3D-printed tablets contained the therapeutic doses of both APIs; however, further optimization of manufacturing processes is required to improve drug content uniformity. The drug release from the printed tablets was sustained, with complete release of CAR observed after 24 h, demonstrating the suitability of the designed drug products for oral delivery.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"314-322"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation and characterization of immediate release 3D printed tablets using hot melt extruded amorphous cyclosporine a filament. 热熔挤压非晶态环孢素A长丝3D打印片剂的制备与表征。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-03-06 DOI: 10.1080/10837450.2025.2472893
Jin-Hyuk Jeong, Chang-Soo Han, Ji-Hyun Kang, Kwang-Hwi Yoo, Woong-Young Jung, Yun-Sang Park, Dong-Wook Kim, Chun-Woong Park
{"title":"Preparation and characterization of immediate release 3D printed tablets using hot melt extruded amorphous cyclosporine a filament.","authors":"Jin-Hyuk Jeong, Chang-Soo Han, Ji-Hyun Kang, Kwang-Hwi Yoo, Woong-Young Jung, Yun-Sang Park, Dong-Wook Kim, Chun-Woong Park","doi":"10.1080/10837450.2025.2472893","DOIUrl":"10.1080/10837450.2025.2472893","url":null,"abstract":"<p><p>3D printing technology is gaining attention as a next-generation approach to drug formulation. Among 3D printing techniques, fused deposition modeling is cost-effective but depends heavily on suitable filaments. Hot melt extrusion enables filament production by incorporating poorly water-soluble drugs like cyclosporine A into polymers to form solid dispersions. However, achieving immediate release formulations with 3D printing remains challenging due to issues such as inadequate tablet disintegration or drug entrapment within the polymer matrix. This study aimed to develop and evaluate immediate release 3D-printed cyclosporine A tablets using HME filaments. Three parameters were modified in the 3D printing process: varying fill speeds, infill densities, and channel lengths. Filaments composed of Kollidon<sup>®</sup> VA 64 and HPC-SSL (1:1) were used to print tablets. Solid-state analysis confirmed cyclosporine A 's amorphous state and partial crystallinity in Xylisorb<sup>®</sup> 300. Dissolution studies revealed that lower infill densities (30%) and fewer walls enhanced drug release by increasing internal void space and reducing hardness. Conversely, greater tablet height (channel length) delayed dissolution. These findings emphasize the critical role of geometric design in drug release, showcasing the potential of 3D printing to create personalized dosage forms tailored to patient needs by optimizing structural parameters.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"295-305"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Saccharomyces cerevisiae-derived vesicles loaded with dextromethorphan as a candidate for the management of neuroinflammation related to Alzheimer's disease. 装载右美沙芬的酿酒酵母衍生囊泡作为阿尔茨海默病相关神经炎症治疗的候选药物
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-03-01 Epub Date: 2025-03-04 DOI: 10.1080/10837450.2025.2470351
Parastoo Valizadeh, Negin Mozafari, Hajar Ashrafi, Reza Heidari, Negar Azarpira, Amir Azadi
{"title":"<i>Saccharomyces cerevisiae</i>-derived vesicles loaded with dextromethorphan as a candidate for the management of neuroinflammation related to Alzheimer's disease.","authors":"Parastoo Valizadeh, Negin Mozafari, Hajar Ashrafi, Reza Heidari, Negar Azarpira, Amir Azadi","doi":"10.1080/10837450.2025.2470351","DOIUrl":"10.1080/10837450.2025.2470351","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a neurodegenerative disease that is associated with neuroinflammation. Dextromethorphan (DXM) exerts neuroprotective effects in many central nervous system injuries and neurodegenerative diseases. The cell wall of <i>Saccharomyces cerevisiae</i> is a cell-based drug delivery system that can be a suitable candidate for targeted drug delivery to the site of inflammation. In this study, nanoparticles (NPs) were prepared from <i>Saccharomyces cerevisiae</i> cell walls, coated with polysorbate-80, and loaded with DXM. NPs had favorable hemolytic behavior with a particle size distribution of 187.25 ± 73.37 nm and a zeta potential of +4.3 mV. Pathological examination in a mouse model of neuroinflammation showed that NPs had the ability to reduce brain inflammation and the adverse effects of DXM.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"259-267"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-acting release of fluocinolone acetonide microspheres using electrospray technology for noninfectious uveitis therapy. 电喷雾技术治疗醋酸氟西诺酮微球非感染性葡萄膜炎的长效释放研究
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-02-01 Epub Date: 2025-02-10 DOI: 10.1080/10837450.2025.2462998
Jiayu Xie, Ke Li, Lusi Chen, Huiying Zhong, Tao Xiao, Lihua Chen, Haibing He, Hongfei Liu, Guoqing Zhang
{"title":"Long-acting release of fluocinolone acetonide microspheres using electrospray technology for noninfectious uveitis therapy.","authors":"Jiayu Xie, Ke Li, Lusi Chen, Huiying Zhong, Tao Xiao, Lihua Chen, Haibing He, Hongfei Liu, Guoqing Zhang","doi":"10.1080/10837450.2025.2462998","DOIUrl":"10.1080/10837450.2025.2462998","url":null,"abstract":"<p><p>Intravitreous long-acting drug delivery system offers an excellent alternative to multiple injections for the treatment of noninfectious uveitis (NIU). However, the adverse effects of non-biodegradable intravitreal implants of fluocinolone acetonide (FA), such as postoperative hypotony and secondary injury during removal of the implant matrix, are frequent occurrence to affect patient's compliance. Herein, biodegradable poly (lactic-co-glycolic acid) (PLGA)-based microspheres (MS) containing fluocinolone acetonide (FA@MS) were prepared using an optimized electrospray technology with a voltage of 10.07 kV and the receiving distance of 9.87 cm. The obtained FA@MS with the average particle size of 2.25 μm possessed the high encapsulation efficiency (94.85%) and drug content (9.48%). <i>In vitro</i> release demonstrated that FA@MS exhibited sustained release for 30 days, and the release characteristic of FA@MS conformed to the Weibull model. <i>In vivo</i> study in a rabbit NIU model indicated that FA@MS continuously released the drug for at least 28 days in vitreum and progressively decreased inflammation of NIU. Furthermore, the intraocular pressure of rabbits treated with blank MS and FA@MS remained the normal level for 28 days, which demonstrated the favorable biosafety of FA@MS. In conclusion, long-acting release of FA@MS provides a promising formulation for NIU treatment. HIGHLIGHTSA biodegradable FA@MS was prepared using the modified electrospray technology for intravitreal administration.FA@MS exhibited the sustained release characteristics for 30 days in the medium of PBS (pH 7.4) with 0.2% Tween 80.The pharmacodynamics indicated that FA@MS could be continuously released for at least 28 days in vitreum to treat NIU.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"210-219"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation development and evaluation of push-pull osmotic pump bi-layered tablets for phencynonate HCl in the treatment of motion sickness. 推拉式渗透泵双层盐酸苯己酸酯片治疗晕动病的配方研制及评价。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-02-01 Epub Date: 2025-02-12 DOI: 10.1080/10837450.2025.2465548
Si-Rui Liu, Wen Lin, Xiang-Yang Xie, Yuan Zeng
{"title":"Formulation development and evaluation of push-pull osmotic pump bi-layered tablets for phencynonate HCl in the treatment of motion sickness.","authors":"Si-Rui Liu, Wen Lin, Xiang-Yang Xie, Yuan Zeng","doi":"10.1080/10837450.2025.2465548","DOIUrl":"10.1080/10837450.2025.2465548","url":null,"abstract":"<p><p>The aim of this study was to develop and evaluate an extended-release (ER) push-pull osmotic pump (PPOP) tablet for phencynonate HCl (PCN), which could release the drug at zero-order profile for a duration of 24 h. The core tablets were designed as bi-layered, primarily composed of sodium chloride and polyethylene oxide (PEO). The central composite design (CCD) within a response surface methodology (RSM) was used to optimize the formulation. An optimized PCN-PPOP tablet formulation was achieved with the following values for key factors: 10 mg NaCl, 70 mg PEO, and 13.56% coating membrane weight gain. It revealed that this formulation could release PCN <i>in vitro</i> at a zero-order manner for 18 h. The <i>in vivo</i> release property of the PCN-PPOP tablet was assessed and contrasted with that of immediate-release (IR) tablet following a single oral administration to beagle dogs. The pharmacokinetic data indicated that the PPOP tablet achieved a sustained <i>in vivo</i> release of PCN, as evidenced by a longer T<sub>max</sub> (7.17 ± 1.83 h) and mean residence time (11.57 ± 1.12 h). This work demonstrated that PCN-PPOP tablet could be designed for oral administration to provide a long-term pharmacological intervention for motion sickness.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"220-232"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NGR-poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate enhances the antitumor effect of quercetin liposomes in triple-negative breast cancer. ngr -聚(2-乙基-2-恶唑啉)-胆固醇酯甲酯增强槲皮素脂质体对三阴性乳腺癌的抗肿瘤作用。
IF 2.6 4区 医学
Pharmaceutical Development and Technology Pub Date : 2025-02-01 Epub Date: 2025-01-18 DOI: 10.1080/10837450.2025.2450434
Chengcheng Zhao, Jian Qin, Dingyu Zhang, Xue Li, Ning Yang, Tingyu Gao, Junliang Song, Yule Song, Shouzhen Huang, Huan Xu
{"title":"NGR-poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate enhances the antitumor effect of quercetin liposomes in triple-negative breast cancer.","authors":"Chengcheng Zhao, Jian Qin, Dingyu Zhang, Xue Li, Ning Yang, Tingyu Gao, Junliang Song, Yule Song, Shouzhen Huang, Huan Xu","doi":"10.1080/10837450.2025.2450434","DOIUrl":"10.1080/10837450.2025.2450434","url":null,"abstract":"<p><p>In this paper, the pH-sensitive targeting functional material NGR-poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate (NGR-PEtOz-CHMC, NPC) modified quercetin (QUE) liposomes (NPC-QUE-L) was constructed. The structure of NPC was confirmed by infrared spectroscopy (IR) and nuclear magnetic resonance hydrogen spectrum (<sup>1</sup>H-NMR). Pharmacokinetic results showed that the accumulation of QUE in plasma of the NPC-QUE-L group was 1.28 times and 2.43 times that of the QUE Solution and QUE-L groups, respectively. The release amount of NPC-QUE-L in an acidic environment was significantly higher than in physiological pH value. The order of the tumor cell inhibition rate in different pH environments was NPC-QUE-L > PC-QUE-L > QUE-L. In addition, the cellular uptake of NPC-modified liposomes was higher than that of PC-modified and unmodified liposomes, indicating that NPC had good pH-sensitivity and targeting. In the triple-negative breast cancer (TNBC) model, the relative tumor proliferation rate of NPC-QUE-L is about 73%, which is better than that of the QUE solution group. Western blot results show that NPC-QUE-L can effectively reduce the expression of α-smooth actin and transforming growth factor-β1 in tumor tissues, and improve the degree of tumor fibrosis. In this study, NPC could endow QUE liposomes with good stability, pH-sensitivity, and targeting, which provides a reference for improving the solubility and targeting of poorly soluble natural drug components.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"137-149"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信